Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Clin Chim Acta. 2019 Feb 18;492:91–94. doi: 10.1016/j.cca.2019.02.017

Table 1.

Comparison of MALDI-TOF MS and immunofixation in distinguishing daratumumab from M-protein.

Immunofixation
Distinguishable Indistinguishable Cannot determine* TOTAL
MALDI-TOF MS Distinguishable 13 13 26
Indistinguishable 1 2 3
Cannot determine** 1 1 2
TOTAL 14 16 1 31
*

IFE result showing the migration pattern of the patient’s original clone is not available

**

M-protein was not detected by Hydrashift